Evidence map›Paper›PMID 27232929›Full record

ArticleBlood cancer journal2016

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.

K Begna, A Abdelatif, S Schwager, C Hanson, A Pardanani, A Tefferi

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2018
    Article
  12. Myeloproliferative neoplasms (MPNs) - Part 1: An overview of the diagnosis and treatment of the "classical" MPNs.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

K BegnaDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
A AbdelatifDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
S SchwagerDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
C HansonDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
A PardananiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
A TefferiDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Agents, AlkylatingBusulfanFemaleHumansMaleMiddle AgedMyeloproliferative DisordersPolycythemia VeraPrimary MyelofibrosisRetrospective StudiesThrombocythemia, EssentialTreatment OutcomeAntineoplastic Agents, AlkylatingBusulfan

Identifiers

PMID27232929
PMCPMC4916303
OpenAlexW2398861476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.